GlassScriptPhysician profile
Megan Brooke Kellar
NPI 1215596168
$7,399.65
in general payments reported to CMS, 2019-2025
20 companies · $954 in 2025
The $954 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $914 · 2022: $1,427 · 2023: $1,441 · 2024: $2,665 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Travel and Lodging: $1,068 · Education: $0.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.18 |
| Travel and Lodging | $1,067.50 |
| Education | $0.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,204.22 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $968.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $817.49 | 2021-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $774.19 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $666.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $411.08 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $308.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $221.14 | 2022-2025 | |
| Insulet Corporation | $216.84 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $152.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.70 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $124.38 | 2021-2025 | Gvoke Hypopen |
| Abbvie INC. | $118.42 | 2022-2023 | |
| Antares Pharma, INC. | $80.98 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $61.99 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.80 | 2022-2023 | |
| Radius Health, INC. | $26.74 | 2023 | Tymlos |
| Averitas Pharma INC. | $23.66 | 2023 | Qutenza |
| Halozyme INC | $22.43 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.94 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Kellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.